Biotek-snakken — April 2023
-
Redeye comments on Acarix following the near-term announcement of two uplifting press releases, including a SEK9.5m directed share issue and a strategic sales partnership expanding the company’s commercial reach with an additional 30 states. https://www.redeye.se/research/892660/acarix-uplifting-news?utm_source=note&utm_medium=email
-
A strategic sales partnership has been formed between Acarix and CompleMed, LLC, a sales organization that focuses on the US cardiology market. CompleMed will contribute 16 sales teams to Acarix’s organization, expanding its geographic market coverage to 43 states and further increasing Acarix’s US footprint. This move aligns with our expectations that Acarix will significantly increase its sales in the US during the latter half of 2023. Our projections indicate that sales will grow from SEK6m i
-
SEK6m in FY 2022 to approximately SEK42m in FY 2023.
-
2 Top Biotech Stocks to Buy Right Now https://www.proinvestor.com/investornyt/965228/2-top-biotech-stocks-to-buy-right-now
-
Danske Bank har øget sin ejerandel i biotekselskabet Gubra til 6,38 pct. af aktiekapitalen, som ejes gennem blandt andet Danica og Danske Invest.
Dermed er banken at regne som storaktionær i Gubra, der gik på børsen mandag før påske.
Det skete til en kurs på 110 kr. Og præcis i det niveau lukkede aktien onsdag, hvor den endte uændret.
.\˙ MarketWire
-
Saniona fortsætter op og der er en aktie, som er ved at rejse sig igen. Der er et kæmpe potentiale i selskabet og hvis/når de får nogle partneraftaler med blandt andet deres blockbuster Tesomet og endelig godkendelse af Tesofensine i Mexico, så er kursen nemt tilbage mellem 25-30 SEK, hvor den kom fra inden de satte deres to studier af Tesomet på standby.
-
Orphazyme på vej med forligsløsning på tvist i USA https://www.proinvestor.com/investornyt/968661/orphazyme-pa-vej-med-forligslosning-pa-tvist-i-usa
-
Inovio Presents Data From Phase 1b Trial With INO-4201 As Ebola Booster For RVSV-ZEBOV https://www.proinvestor.com/investornyt/968741/inovio-presents-data-from-phase-1b-trial-with-ino-4201-as-ebola-booster-for-rvsv-zebov
-
Stimen af opkøb fortsætter: GSK To Buy BELLUS Health In US$2.0 Bln Deal https://www.proinvestor.com/investornyt/969145/gsk-to-buy-bellus-health-in-us20-bln-deal
-
Basilea Provides Updated Timeline For NDA Submission For Antibiotic Ceftobiprole To FDA https://www.proinvestor.com/investornyt/969136/basilea-provides-updated-timeline-for-nda-submission-for-antibiotic-ceftobiprole-to-fda
-
FDA Approves Omisirge Cell Therapy For Blood Cancers https://www.proinvestor.com/investornyt/969139/fda-approves-omisirge-cell-therapy-for-blood-cancers
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind